Find below a list of all Satellite Symposia of EANM’26.
The content presented on this page is constantly updated.
Symposium1
PharmaLogic Sunday, October 18, 2026 (13:15 – 14:45)
Hall E2 (livestream available)
Title: Scaling Radiopharmaceutical Therapeutics for Commercial manufacturing
Framework: Introduction: 5 min, 3 x 15 min for each presentation, plus final 25 min Q&A discussion
Objectives:
• GMP regulatory framework for large-scale RLT manufacturing: Examine the GMP requirements applicable to the commercial-scale manufacture of radioligand therapies (RLTs) across major global markets. Assess how EU GMP requirements, including Annex 1, and U.S. cGMP requirements under 21 CFR Part 211 apply to therapeutic radiopharmaceutical manufacturing, with particular focus on contamination control strategy (CCS), aseptic processing, facility and operational controls, and pharmaceutical quality systems. Extend the assessment to other key jurisdictions, including Japan and China, identifying areas of regulatory convergence and divergence and the implications for sponsors seeking to establish a globally aligned manufacturing and supply strategy.
Speaker: Nina Aalén Dørre | Bayer | VP, CMC Radiopharm Lead
• Building the right capabilities to successfully scale RLT manufacturing: Examine the practical requirements for building, expanding, or adapting manufacturing capacity for radioligand therapies (RLTs), from facility and process design through operational readiness. Address key considerations including hot cell and shielding design, equipment and automation strategy, radiation safety and material flows, facility and equipment qualification, process and analytical validation, and quality system implementation. Highlight the unique challenges associated with short half-life products, including compressed manufacturing and release timelines, decentralized versus centralized manufacturing models, supply chain coordination, and the need to integrate production, quality control, release, and distribution within tightly controlled time windows.
Speaker: Silje Sivesind | Agilera | Production Director
• Manufacturing technology – what will RLT manufacturers need tomorrow? Explore the next generation of manufacturing technologies required to support the continued growth and industrialization of radioligand therapies (RLTs). Examine the evolving needs of large pharmaceutical and biotechnology companies, including greater automation, throughput, flexibility, closed processing, digital integration, real-time monitoring, and reduced operator intervention and radiation exposure. Consider how RLT manufacturers and equipment suppliers can collaborate earlier and more strategically to develop scalable, standardized, and GMP-ready manufacturing platforms. Address how responsibilities should be defined and shared between manufacturers and equipment suppliers for GMP compliance, qualification and validation, data integrity, contamination control, and radiation protection, and how equipment design can better integrate pharmaceutical quality and safety requirements from the outset.
Speaker: Matteo Camaggi | TEMA Sinergie | Key Account Manager & Sales Engineer – Radiopharma & Nuclear Medicine
Symposium2
Medscape Education Global Sunday, October 18, 2026 (13:15 – 14:45)
Hall F1 (livestream available)
Title:
Combination Radiopharmaceuticals in mCRPC: Integrating the Latest Data Into Clinical Practice
Combination Radiopharmaceuticals in mCRPC: Integrating the Latest Data Into Clinical Practice
Moderator:
Sabina Dizdarevic, MD, MSc, PhD, FRCP
Speakers:
Elena Castro, MD, PhD; Francis Xavier Sundram, MBBCh, FRCP, FRCPI; Bertrand Tombal, MD, PhD
Agenda:
- Welcome and Introduction
- Clinical Evidence: Latest Data Updates and the Radiopharmaceutical Combination Landscape in Early mCRPC
- Patient Perspectives and Humanizing Care Plan Development
- Sequencing Considerations and Expanding the Therapeutic Toolbox
- Key Takeaways and Q&A
Summary:
Radiopharmaceutical combinations are reshaping how we manage metastatic castration-resistant prostate cancer (mCRPC). This 90-minute live town hall gathers a multidisciplinary panel of experts from the fields of nuclear medicine, medical and radiation oncology, and urology who will lay out what the emerging evidence for combination therapies can mean for your clinical practice. Together they will examine the latest clinical data, clarify updated guideline recommendations, offer practical strategies for treatment sequencing, and make the case for bone-protecting agents in early mCRPC care. Interactive polling and live Q&A keep the conversation grounded in real-world practice, and short patient documentaries provide a vital perspective into the lived patient experience.
Supported by an independent educational grant from Bayer.
Symposium3
Telix Pharmaceuticals Sunday, October 18, 2026 (13:15 – 14:45)
Hall F2 (livestream available)
The Future Doesn’t Wait
The Next Era of Theranostics in Urologic Oncology
Moderator : Prof. Jeremie Calais
The Theranostic revolution
Prof. Jeremie Calais
The Evolving Role of PSMA-PET in Prostate Cancer
Where Are We Going?
Optimizing Clinical Practice
Prof. Ken Herrmann & Prof. Munir Ghesani
Next-Generation PSMA Therapeutics: Overcoming Today’s Challenges
Overcoming current challenges in PCa RNT
The OPTIMAL experience
Prof. Daniela Oprea-Lager & Prof. Louise Emmett
Panel discussion
All Speakers
How Extending PCa theranostic Success to broader GU diseases ?
Prof. Jeremie Calais
Moderator & Speaker :
Prof. Dr. Jeremie Calais : Professors of nuclear medicine at Gustave Roussy, IGR and Université Paris-Saclay, Paris, France
Speakers :
Prof. Dr. Ken Herrmann : Professor of nuclear medicine at the University Hospital Essen, Germany
Prof. Dr. Munir Ghesani : Professor of nuclear medicine and Chief Medical Officer at United Theranostics, USA
Prof. Dr. Daniela Oprea-Lager : Professor of nuclear medicine at the Department of Medical Imaging, Radboud University Medical Center, Nijmegen, the Netherlands
Prof. Dr. Louise Emmett : Director of Theranostics and Nuclear Medicine St Vincent’s Hospital, Sydney, Australia
Symposium4
ABX advanced biochemical compounds Sunday, October 18, 2026 (13:15 – 14:45)
Hall G2
SEEING MORE, TREATING BETTER: THE EVOLVING ROLE OF PSMA THERANOSTICS
Welcome and Introduction
Prof. M. Eiber, Prof. F.Giesel
5 minutes
Beyond Detection: Phenotyping Prostate Cancer with PSMA PET
Prof. Rudolf Werner
Department of Nuclear Medicine, LMU University Hospital Munich
20 minutes
From Images to Insights: Artificial Intelligence in PSMA Theranostics
Prof. Mijin Yun
Department of Nuclear Medicine, Yonsei University Hospital Seoul, Soth Korea
20 minutes
PSMA-Theranostics in Japan – Implementation into clinical practice
Prof. Tadashi Watabe
Department of Nuclear Medicine, University of Osaka, Japan
20 minutes
PSMA PET/CT in Clinical Practice: From New Guidelines to Prognostic Biomarkers for Treatment Response and Progression-Free Survival
Dr. Karen Buch-Ohlsen
Department of Nuclear Medicine, University Hospital Lillebaelt Vejle, Denmark
20 minutes
Closing remarks
Prof. M. Eiber, Prof. F.Giesel
5 minutes
Symposium5
Siemens Healthineers Sunday, October 18, 2026 (13:15 – 14:45)
Hall K (livestream available)
Symposium title:
Evolution in action: Advancing our molecular imaging portfolio
Program text:
Discover how continuous innovation is shaping the future of molecular imaging at this lunch symposium, which highlights evolving developments across PET/CT, PET/MR and AI tools. Learn about improved time-of-flight performance on the Biograph Quadra PET/CT, AI-assisted reading and reporting with syngo.via, and more.
Speakers:
- Prof. Dr. Michael Schäfers MD – Universität Münster, GER
- Prof. Dr. Alexander Hammers – Kings College London, UK
- Prof. Dr. Mohsen Beheshti MD, FEBNM, FASNC – Paracelsus Medical University, Salzburg, AT
Symposium6
GE Healthcare (PDx) Sunday, October 18, 2026 (13:15 – 14:45)
Hall G1 (livestream available)
TITLE:
Molecular Imaging in Dementia and Co-Pathologies with Alzheimer Disease
Moderator:
Pr Antoine Verger, Nuclear Physician (CHRU Nancy, France)
AGENDA:
- Pr Federica Agosta, Neurologist (UniSR, Milan, Italy)
When Dementia Overlaps: The Clinical Impact of Co-Pathologies with Alzheimer’s Disease - Pr Matthias Brendel, Nuclear Physician (University of Munich, Germany)
Molecular Imaging at the DLB–AD Intersection: Differential Diagnosis and Co-Pathology in Practice - Pr Dr Javier Arbizu, Nuclear Physician (University of Navarra, Spain)
Relevance of amyloid PET Imaging in AD diagnosis
SUMMARY
This symposium explores the growing role of molecular imaging in improving the diagnosis and management of dementia, starting from the complex overlap between Alzheimer’s disease (AD) and other neurodegenerative disorders. Through a multidisciplinary perspective combining neurology and nuclear medicine, the faculty will discuss how co-pathologies can influence clinical presentation, diagnostic pathways, and patient management.
Topics include the clinical impact of overlapping dementia pathologies, the value of molecular imaging in differentiating Dementia with Lewy Bodies (DLB) from Alzheimer’s disease, and the role of amyloid PET imaging in supporting accurate and timely AD diagnosis. Together, these sessions highlight how advanced imaging techniques can help clinicians navigate diagnostic complexity and enable more personalized patient care.
Symposium7
GE Healthcare Monday, October 19, 2026 (13:15 – 14:45)
Hall B
Real-World Evidence and Innovation in Molecular Imaging and Theranostics
Moderator:
Prof. Irene Virgolini, Medical University of Innsbruck, Austria
Speakers
Dr. Lisa Rowley, University Hospitals Coventry and Warwickshire, UK
Prof. Frédéric Courbon, Cancer University Institute of Toulouse, France
Prof. Martin Huellner, University Hospital of Zurich, Switzerland
Dr. Ties Mulders, University Medical Center Rotterdam, Netherlands
Q&A and panel discussion with the speakers and
Dr. Adi Hanuka, AI Director, GE HealthCare
Dr. Ilya Gipp, Chief Medical Officer – Oncology, GE HealthCare
Symposium8
Curium Monday, October 19, 2026 (13:15 – 14:45)
Hall F1 (livestream available)
Title: Expanding the Horizons of PSMA Theranostics and beyond
The diagnostic landscape of PSMA targeting – the role of 18F-DCFPYL
Prof. Dr. Irene Andrea Burger
Nuclear Medicine Physician and Radiologist
Kantonsspital Baden, Baden, Switzerland
Standardized reporting – What is new and what do we need?
Prof. Dr. Matthias Eiber
Nuclear Medicine Physician and Radiologist
Technical University of Munich (TUM), University Hospital rechts der Isar, Munich, Germany
Where is PSMA therapy going – a future perspective on opportunities and limitations
Prof. Dr. Jeremie Calais
Nuclear Medicine Physician
Gustave Roussy, Villejuif, France
University of California, Los Angeles (UCLA), Los Angeles, CA, USA
Panel Discussion Moderator
Prof. Dr. Bertrand Tombal
Urologist, Surgeon
University Hospitals Saint-Luc, Brussels
Catholic University, Louvain, Belgium
Symposium9
Novartis Pharma Monday, October 19, 2026 (13:15 – 14:45)
Hall F2 (livestream available)
Shaping the Future of Radioligand Therapy: From Drug Development to Clinical Application
Summary:
This expert-led symposium brings together a multidisciplinary faculty to explore the evolving landscape of radioligand therapy (RLT) development—from foundational principles and approved therapies to novel targets, radionuclides, and indications. The panel will discuss key challenges and opportunities in early clinical development, including the role of dosimetry, safety reference thresholds, and other available evidence to inform development decisions. The symposium will conclude by looking ahead to what is needed to successfully integrate novel RLTs into routine clinical practice.
Faculty:
• Chair: Ken Herrmann, University Hospital Essen, Essen, Germany
• Christophe Deroose, University Hospitals Leuven, Leuven, Belgium
• Oliver Sartor, East Jefferson General Hospital Cancer Center, New Orleans, LA, USA
• Caroline Stokke, Oslo University Hospital Oslo, Norway
Agenda:
13:15–13:20
Welcome, introduction, and educational objectives
Ken Herrmann (Chair & Moderator)
13:20–13:25
History and evolution of radioligand therapies
Ken Herrmann
13:25–13:45
The evolving radioligand therapy landscape: Building on an established platform to unlock novel opportunities
All faculty
13:45–14:30
Navigating early clinical development of radioligand therapies: Challenges and opportunities
All faculty
14:30–14:40
Novel radioligand therapies in clinical practice: Meeting today’s needs, shaping tomorrow’s standards
All faculty
14:40–14:45
Conclusion and key takeaways
Ken Herrmann
Symposium10
United Imaging Healthcare Monday, October 19, 2026 (13:15 – 14:45)
Hall K (livestream available)
Living Body, Precision Imaging: Dynamic and Quantitative PET/CT
Molecular imaging is moving from static images to quantitative imaging of biological changes over time. Join an international panel to explore what next-generation PET systems can now measure, and what that means in daily practice.
The discussion will cover dynamic acquisition and quantification across whole-body and brain imaging, and in systemic diseases such as myeloma and leukemia, as well as how reconstruction methods influence image quality, radiation dose, and scan time.
As the speakers work with diverse PET/CT scanners and axial field-of-view, the session will focus on a shared practical question: how do these differences change the way we scan, quantify, and report?
Join us to discover how these technologies translate into actionable clinical care.
We are delighted to welcome our keynote speakers:
Prof. Dr. Sibylle Ziegler, Ph.D.
Head of PET/CT Research, Department of Nuclear Medicine, Hannover, Germany
Using all Four Dimensions in TB-PET Data Analysis to Image Biology
Dr. Cristina Nanni, Ph.D.
Nuclear Medicine Physician, Adjunct Professor, Bologna, Italy
Contribution of Total Body PET in Multiple Myeloma and Acute Leukemia.
Prof. Dr. Florent Besson, M.D., Ph.D.
Professor of Nuclear Medicine, AP-HP, CHU Bicêtre; Université Paris-Saclay; CEA/CNRS/Inserm/BioMaps, Le Kremlin-Bicêtre, France
Deep Progressive Reconstruction in PET: Changing the Way We Practice?
Dr. Greet Vanderlinden, Ph.D.
Postdoctoral Researcher / Special Research Associate, Leuven, Belgium
Ultra-High-Resolution Brain PET Quantification: Towards Non-invasiveness?
You Really should Get to Know Us.
Explore our website at https://global.united-imaging.com/en/ or scan the provided QR Code.
Symposium11
BlueEarth Diagnostics Monday, October 19, 2026 (13:15 – 14:45)
Hall G1 (livestream available)
This is a non-promotional symposium sponsored and organised by Blue Earth Diagnostics
The PET Effect: Transforming Prostate Cancer Care Yesterday, Today & Tomorrow
Faculty:
• Prof. Stefano Fanti, University of Bologna, Italy
• Prof. Daniela Oprea-Lager, Radboud University, Nijmegen, The Netherlands
• Prof. Wolfgang Fendler, University Hospital Essen, Germany
First-generation PET tracers
Begin the journey by revisiting the lessons learned from first-generation PET tracers and how they helped lay the foundations for modern prostate cancer imaging.
Transforming Clinical Practice Through Molecular Imaging
Explore how PSMA PET is shaping today’s clinical practice, from recurrence assessment to interpretation challenges and the complexities of PSMA-negative disease.
Imaging and Imagining the Future of Prostate Cancer
Look ahead to a rapidly expanding PET landscape and explore how new risk tools, response frameworks and emerging targets could broaden the future of prostate cancer care.
Q&A
Symposium12
Spectrum Dynamics Medical Monday, October 19, 2026 (13:15 – 14:45)
Hall E2 (livestream available)
EANM Spectrum Dynamics Symposium – “Driving Precision Nuclear Medicine with 360° CZT SPECT/CT: Quantitation, AI, and Clinical Impact”
Pr. Denis Agostini, MD, PhD
Head of Nuclear Medicine Department – University Hospital of Caen, France
Host, Moderator, Introductions
Laetitia Imbert, PhD
Medical Physicist – University Hospital of Nancy, France
360 CZT SPECT/CT Quantitation and validation of high energy and AI applications
Désirée DEANDREIS, MD, PhD
Head of Nuclear Medicine Department – Institut Gustave Roussy, France
From Discovery to Daily Practice: Clinical and Research Applications of VERITON-CT CZT SPECT/CT in Oncology and Theranostics
Daniel Juneau, MD
Assistant Clinical Professor – Department of Medicine, Université de Montréal, Canada
Optimizing clinical and research workflows in a large tertiary center using a 360 CZT SPECT/CT
Symposium13
Boston Scientific Monday, October 19, 2026 (13:15 – 14:45)
Hall G2 (livestream available)
Y-90 radioembolisation: Translating Real-World evidence into practice – Advancing personalised dosimetry and treatment optimisation in HCC
This 60-minute symposium reviews how personalised dosimetry and microsphere characteristics shape outcomes in radioembolisation with TheraSphere Y-90 Therapy for HCC. Faculty will interpret the clinical evidence supporting personalised dosimetry, explain how high radiation per microsphere influences CPN and clinical outcomes, and show how dosimetry principles and recent real-world evidence can be applied to optimise treatment planning. Lectures are followed by an interactive case discussion applying these principles to complex HCC cases.
Program:
1:15 – 1:20pm
Prof M. Lam
Welcome and faculty presentation
1:20 – 1:35pm
Prof M.Lam
TheraSphereTM High Specific Activity: Why Radiation per Microsphere Matters
1:35-1:50pm
Prof E.Garin
Personalised Dosimetry in Clinical Practice: Redefining HCC Treatment Strategies
1:50-2:05pm
Prof La Fougere
Can We Reliably Predict Absorbed Dose? From MAA-Based Planning to Personalised Dosimetry
2:05-2:20pm
Prof M.Lam
(discussant All)
Interactive Case Discussion: Applying Personalised Dosimetry in Complex HCC
Faculty:
Prof. Marnix Lam
Moderator & Speaker
M.Lam@umcutrecht.nl
University Medical Center Utrecht, Utrecht, The Netherlands
Prof. Etienne Garin
Speaker
e.garin@rennes.unicancer.fr
University of Rennes, Rennes, France
Prof. Christian La Fougère
Speaker
christian.lafougere@med.uni-tuebingen.de
University Hospital Tübingen, Tübingen, Germany
Symposium14
OmniAb Tuesday, October 20, 2026 (13:15 – 14:45)
Hall G1
Title: OmniUltra™: An In Vivo Discovery Platform for Structured Peptides to Enable Radioligand Therapy
Speaker: Christel Iffland, PhD, Sr. Vice President, R&D Portfolio Management and Technology Operations, OmniAb
Summary: OmniUltra is an in vivo discovery platform designed to identify compact, target-selective peptide ligands with potential advantages for radioligand therapy and other applications. Peptides are generated and optimized in vivo, using natural selection mechanisms to enrich for high-affinity target engagement, specificity, favorable size, and tunable pharmacokinetic clearance. OmniUltra harnesses immune-system biology which may enable identification of drug-like binders earlier in discovery compared to traditional approaches.